{"id":629381,"date":"2022-12-07T20:58:02","date_gmt":"2022-12-07T20:58:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=629381"},"modified":"2022-12-07T20:58:02","modified_gmt":"2022-12-07T20:58:02","slug":"adultonset-still-disease-market-to-register-incremental-growth-during-the-forecast-period-20222032-estimates-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adultonset-still-disease-market-to-register-incremental-growth-during-the-forecast-period-20222032-estimates-delveinsight_629381.html","title":{"rendered":"Adult-onset Still Disease Market to Register Incremental Growth During the Forecast Period (2022-2032), Estimates DelveInsight"},"content":{"rendered":"
\n
\"Adult-onset<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Adult-onset Still Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adult-onset Still Disease market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Adult-onset Still Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"\"<\/p>\n

Adult-onset Still Disease: An Overview<\/strong><\/p>\n

Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that affects the entire body (systemic disease). The cause of the disorder is unknown (idiopathic). It has similar symptoms to systemic-onset juvenile idiopathic arthritis – fever, rash, and joint pain. The specific symptoms and frequency of episodes vary from person to person, and the disorder’s progression is difficult to predict. In some individuals, the disorder appears suddenly, disappears almost as quickly, and may not return. In other people, adult-onset Still’s disease is a chronic, potentially disabling condition.<\/p>\n

Adult-onset Still Disease Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Adult-onset Still Disease market size<\/strong> by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.<\/p>\n

The report gives complete detail of the Adult-onset Still Disease market trend<\/strong> for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.<\/p>\n

Adult-onset Still Disease Epidemiology Assessment <\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. <\/p>\n

Adult-onset Still Disease Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adult-onset Still Disease market<\/strong> or expected to be launched during the study period. The analysis covers the Adult-onset Still Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. <\/p>\n

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n

The report also covers the Adult-onset Still Disease Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Learn How Adult-onset Still Disease Market Will Evolve by 2032 @ <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/adult-onset-still-disease-market<\/a><\/strong><\/p>\n

Adult-onset Still Disease Therapeutics Analysis<\/strong><\/p>\n

Many different therapies have been tried for individuals with adult-onset Still’s disease. No one treatment has proven consistently effective in all cases. A variety of different drugs taken alone or in combination may be used to treat affected individuals. Nonsteroidal anti-inflammatory drugs (NSAIDs) are often used to treat symptoms of inflammation. Fever, joint pain and bone pain have responded to treatment with these drugs. Other painkillers (analgesics) such as Tylenol (acetaminophen) may also be used. In 2020, the U.S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) to treat patients with active Still’s disease, including Adult-onset Still’s disease.<\/p>\n

There are approx. 10+ key companies<\/strong> which are developing therapies for Adult-Onset Still Disease. Currently, AB2 Bio Ltd.<\/strong> is leading the therapeutics market with its Adult-Onset Still Disease drug candidates in the mid to advanced stage of clinical development. <\/em><\/p>\n

The Leading Companies in the Adult-onset Still Disease Therapeutics Market Include:<\/strong><\/p>\n